Bowel Preparation for Pediatric Colonoscopy

Mamula, Petar; Nema, Noor

doi:10.3389/fped.2021.705624

Cited by 6 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are currently no standard methods for pediatric bowel preparation, but a wide variety of regimens have been used in clinical studies and clinical practice [10,11]. According to current guidelines [1,11,12,13], bowel cleansing preparation for colonoscopy in pediatric patients should be personalized based on the patient's age, clinical state, and anticipated willingness or ability to comply with the selected method [14].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of a new low-volume PEG with citrate and simethicone bowel preparation for pediatric elective colonoscopy: Phase 3 RCT

Russo,

Alvisi,

Romano

et al. 2024

Endosc Int Open

View full text Add to dashboard Cite

Background Currently available PEG-based preparations continue to represent a challenge in children. The aim of this study was to compare the efficacy and safety of a new low-volume PEG preparation with a conventional PEG-electrolyte solution (PEG-ES) in children and adolescents. Methods This was a multicenter, randomized, observer-blind, parallel-group, phase III clinical trial, where patients were randomized between PMF104 (Clensia) and a conventional PEG-ES (Klean-Prep), and stratified by age stratum (2-<6;6-<12;12-<18 years). The primary endpoint was to test the non-inferiority of PMF104 versus PEG-ES, in terms of colon cleansing. Safety, tolerability, acceptability, palatability, and compliance were also assessed. Efficacy endpoints were analysed in the Per Protocol Set (PPS) and Full Analysis Set (FAS), safety and tolerability endpoints in the Safety Set (SAF). Results Of the 356 patients enrolled, 258 were included in the PPS, 346 in the FAS and 351 in the SAF. Non-inferiority of PMF104 was confirmed for children aged >6 years and for all age groups in PPS and FAS, respectively. Optimal compliance was reported more frequently in the PMF104 than in the PEG-ES group, in both PPS (86.1% vs. 68.4%) and FAS (82.9% vs. 65.3%). Both preparations were equally safe and tolerable. Palatability and acceptability were considered better in the PMF104 group than in the PEG-ES group (27.1% vs. 15.3% and 15.3% vs. 3.5%, respectively). Conclusions In children aged 6-17 years, the new low-volume product PMF104 is non-inferior to the reference PEG-ES in terms of bowel cleansing, safety, and tolerability, with slightly better results in compliance, palatability, and acceptability.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of a new low-volume PEG with citrate and simethicone bowel preparation for pediatric elective colonoscopy: Phase 3 RCT

Russo,

Alvisi,

Romano

et al. 2024

Endosc Int Open

View full text Add to dashboard Cite

show abstract

Surgical management of rare tumors (Part 1)

Stetson,

Saluja,

Cameron

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

With an annual cumulative occurrence of approximately 15,000 in North America, all childhood cancers are rare. Very rare cancers as defined by both the European Cooperative Study Group for Rare Pediatric Cancers and the Children's Oncology Group fall into two principal categories: those so uncommon (fewer than 2 cases/million) that their study is challenging even through cooperative group efforts (e.g., pleuropulmonary blastoma and desmoplastic small round cell tumor) and those that are far more common in adults and therefore rarely studied in children (e.g., thyroid, melanoma, and gastrointestinal stromal tumor). Treatment strategies for these latter tumors are typically based on adult guidelines, although the pediatric variants of these tumors may harbor different genetic signatures and demonstrate different behavior. If melanoma and differentiated thyroid cancer are excluded, other rare cancer types account for only 2% of the cancers in children aged 0 to 14. This article highlights several of the most common rare tumor types.

show abstract